Previous studies revealed that glioma patients with mutant IDH exhibited a more favorable response to current therapy including radiation and chemotherapy, implying the correlation between molecular alterations and prognosis (Cairncross et al., 2014). This evidence concerns the gene IDH1 and central nervous system cancer.